Glucose Health, Inc. SEC filings GLUC
Glucose Health, Inc. has 140 filings in SEC EDGAR's recent list, going back to Dec 7, 2007. Its latest annual report, Form 10-K, was filed on Mar 29, 2017 for the period ended Dec 31, 2016. The latest quarterly report (Form 10-Q) was filed on Nov 14, 2017, covering the quarter ended Sep 30, 2017. The most recent current report (Form 8-K) was filed on Apr 11, 2017 (auditor change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| D | Filing | Oct 19, 2026 | — |
| D | Filing | Oct 7, 2026 | — |
| D | Filing | Oct 6, 2026 | — |
| D | Filing | Oct 6, 2026 | — |
| D | Filing | Sep 10, 2026 | — |
| D | Filing | Jul 7, 2026 | — |
| D | Filing | Feb 4, 2026 | — |
| D | Filing | Dec 5, 2025 | — |
| D/A | Filing | Jan 19, 2024 | — |
| D | Filing | Dec 7, 2023 | — |
| RW | Filing | Jun 28, 2023 | — |
| D | Filing | Mar 9, 2021 | — |
| D | Filing | Jun 19, 2020 | — |
| D | Filing | May 12, 2020 | — |
| D | Filing | May 3, 2019 | — |
| 15-12G | Deregistration | Apr 16, 2018 | — |
| NT 10-K | Filing | Apr 2, 2018 | Dec 31, 2017 |
| NT 10-Q | Filing | Aug 14, 2017 | Jun 30, 2017 |
| NT 10-Q | Filing | Nov 14, 2016 | Sep 30, 2016 |
| NT 10-Q | Filing | Aug 15, 2016 | Jun 30, 2016 |
| NT 10-Q | Filing | May 16, 2016 | Mar 31, 2016 |
| NT 10-K | Filing | Mar 30, 2016 | Dec 31, 2015 |
| NT 10-Q | Filing | Nov 16, 2015 | Sep 30, 2015 |
| NT 10-Q | Filing | Aug 14, 2015 | Jun 30, 2015 |
| NT 10-Q | Filing | May 15, 2015 | Mar 31, 2015 |
| 8-A12G | Filing | May 1, 2015 | — |
| UPLOAD | Letter from the SEC | Jul 1, 2014 | — |
| NT 10-K | Filing | Mar 31, 2014 | Dec 31, 2013 |
| CORRESP | Letter to the SEC | Mar 19, 2014 | — |
| UPLOAD | Letter from the SEC | Mar 6, 2014 | — |
| CORRESP | Letter to the SEC | Feb 25, 2014 | — |
| CORRESP | Letter to the SEC | Jan 28, 2014 | — |
| UPLOAD | Letter from the SEC | Jan 14, 2014 | — |
| CORRESP | Letter to the SEC | Jan 2, 2014 | — |
| UPLOAD | Letter from the SEC | Dec 18, 2013 | — |
| CORRESP | Letter to the SEC | Dec 4, 2013 | — |
| UPLOAD | Letter from the SEC | Nov 20, 2013 | — |
| NT 10-K | Filing | Mar 29, 2012 | Dec 31, 2011 |
| NT 10-Q | Filing | Nov 14, 2011 | Sep 30, 2011 |
| UPLOAD | Letter from the SEC | Oct 27, 2011 | — |
| CORRESP | Letter to the SEC | Sep 28, 2011 | — |
| UPLOAD | Letter from the SEC | Sep 20, 2011 | — |
| NT 10-Q | Filing | Aug 12, 2011 | Jun 30, 2011 |
| NT 10-Q | Filing | May 16, 2011 | Mar 31, 2011 |
| NT 10-K | Filing | Mar 31, 2011 | Dec 31, 2010 |
| NT 10-Q | Bio-solutions form 12b25 093010 | Nov 15, 2010 | Sep 30, 2010 |
| NT 10-K | Bio-solutions form 12b25 12/31/09 | Mar 31, 2010 | Dec 31, 2009 |
| EFFECT | Filing | May 6, 2009 | — |
| CORRESP | Letter to the SEC | May 4, 2009 | — |
| UPLOAD | Letter from the SEC | Apr 24, 2009 | — |
| CORRESP | Letter to the SEC | Apr 23, 2009 | — |
| 10KSB | Bio-solutions form 10-ksb for the period december 31, 2007 | Apr 10, 2008 | Dec 31, 2007 |
| NT 10-K | Bio-solutions corp. form nt 10-k for the period 12/31/07 | Apr 1, 2008 | Dec 31, 2007 |
| EFFECT | Filing | Dec 21, 2007 | — |
| SB-2 | Bio-solutions corp. form sb-2 | Dec 7, 2007 | — |
Showing 55 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- GLUC (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bentonville, AR
- SEC filer status
- Smaller reporting company
- SEC CIK
- 1420108
- Former names
- Bio-Solutions Corp. (until Dec 16, 2014)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.